Zenosense, Inc. (ZENO) Begins Development of Lung Cancer Detection Device

Today before the opening bell, healthcare technology company Zenosense announced development efforts will commence on a detection device for lung cancer. Zenosense will be partnering with Sgenia, its development partner for an MRSA detection device, in these development operations. Full details are given in Zenosense’s Form 8-k, filed on July 24, 2014.

The device calls for similar technology and principles (e.g., VOC signature detection) that are being used in the MRSA device. A revised development budget for both devices will require $1.41 million on top of the $527k that already has been spent. Lung cancer is the leading cause of cancer death in the United States; a low five-year survival rate of 16% is due largely to late-stage diagnosis. Lung cancer is also difficult to diagnose, as it requires several types of tests for confirmation. Among other tests, for instance, a doctor can refer a patient for an expensive tomography scan, followed by a biopsy for a definitive conclusion.

With Sgenia, Zenosense believes there is potential for the device that has the capacity to detect lung cancer in its earlier stages. Sgenia’s patent-pending sensory technology opens up potential for the device to be manufactured with standard components and to offer it at lower cost. Substantial progress already has been made on the MRSA device. In development operations of both devices, there is a top-tier development team in place, consisting of experts in nanotechnology, sensors, high-level mathematics, molecular biology, and biochemistry.

The lung cancer device could be deployed to healthcare settings, where patients could undergo a breathing test on the device as an indicator test of lung cancer, whether they are symptomatic or undergoing a routine medical examination. Zenosense anticipates that the device would be more effective in lung cancer detection than a tomography scan.

As R&D moves forward, Zenosense has put collaborations and partnerships in place with hospitals, universities, and a private laboratory in the fields of sensors, polymer electrochemistry, microbiology, infectious disease, pneumology, chromatography, and microorganism identification. Sgenia is also in talks with a prestigious hospital in Madrid, which has conducted substantial trials on cancer VOCs and there has access to significant data that directly applies to development of a lung cancer-detecting device.

For more information, visit: www.zenosense.net

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net